Sareum Holdings PLC (FRA:RYH0)

Half Year 2025 Sareum Holdings PLC Earnings Call Transcript

Mar 25, 2025 / 02:00 PM GMT

Release Date Price: €0.119 (-7.75%)

Transcript

Key Points

Positve

Sareum Holdings PLC (STU:RYH0) completed a successful Phase 1 study for SDC 1,801, showing high blood exposure and no serious adverse events.
The company regained control of SRA 737, a cancer drug, increasing their economic interest to 63.5%.
Sareum Holdings PLC is well-funded with a cash position of over 4 million pounds, bolstered by recent share subscriptions and tax credits.
The company demonstrated strong preclinical and clinical data for SDC 1,801, indicating potential best-in-class status for autoimmune disorders.
Sareum Holdings PLC is actively pursuing licensing and development options for SRA 737, with promising preclinical data supporting its use in combination therapies.

Negative

There is a delay in the commencement of 16-week toxicology studies for SDC 1,801 due to the need to resynthesize the drug.
The company experienced a negative experience with the UK MHRA, impacting their decision on future trial locations.
Sareum Holdings PLC's share price has not been favorable, and they are actively seeking ways to improve shareholder value.
The company faces challenges in balancing the risk and cost of drug synthesis and storage for future studies.
There is uncertainty regarding the timing and outcome of potential licensing deals for SDC 1,801 and SRA 737, which could impact future funding and development plans.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SAR.L - Sareum Holdings PLC
Half Year 2025 Sareum Holdings PLC Earnings Call
Mar 25, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the SIEM Holdings PLC Interim Results Investors presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to executive Chairman Doctor Stephen Parker. Good afternoon to you.

---

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.